Related Experiment Video
Updated: Aug 19, 2025

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Access to antiviral therapy for chronic hepatitis B during COVID-19
Marilia Rocha Bertolli1, Priscilla Alves Rocha1, Vanusa Barbosa Pinto1
1Universidade de São Paulo, Faculty of Medicine, Hospital das Clínicas, Pharmacy Division - São Paulo (SP), Brazil.
Insights
During the COVID-19 pandemic, access to hepatitis B antiviral therapy was limited for women and older adults. A home medication delivery program improved access for chronic hepatitis B patients.
Area of Science:
- Hepatology
- Public Health
- Infectious Diseases
Background:
- Hepatitis B is a significant global health issue.
- The COVID-19 pandemic has disrupted healthcare access for chronic disease management.
- Contingency measures may have impacted hepatitis B treatment availability.
Purpose of the Study:
- To assess access to antiviral therapy for chronic hepatitis B patients during the COVID-19 pandemic.
- To identify patient groups with challenges in accessing hepatitis B treatment.
- To evaluate the effectiveness of a medication delivery program.
Main Methods:
- Descriptive analysis of treatment access for 225 chronic hepatitis B patients.
- Study conducted at a tertiary university hospital in São Paulo, Brazil.
- Data collected from April to December 2020.
Main Results:
- The Home Medication Delivery Program (HMDP) served 64% of patients.
- Women (56%) and individuals over 48 years old (70%) showed poorer access to antiviral therapy.
- Patients in the HMDP (68%) had improved access.
Conclusions:
- The study identified specific demographics at higher risk of limited access to hepatitis B antiviral therapy.
- A medication delivery system demonstrated benefits in maintaining treatment access during a public health crisis.
- Findings aid in optimizing public health strategies during pandemics.
Objective:
Hepatitis B is an important public health concern. Currently, the COVID-19 pandemic is a major challenge for health systems, and the access to pharmacologic and non-pharmacologic treatment of chronic diseases, such as hepatitis B, may have been affected due to the contingency measures. This study aimed to evaluate the access to antiviral therapy during the ongoing pandemic.
Methods:
This was a descriptive analysis of the access to treatment for chronic hepatitis B at a tertiary-level university hospital in São Paulo, integrated with the Brazilian health system. The study was conducted from April to December 2020.
Results:
Access to antiviral therapy for 225 patients was assessed. The majority of the population was male (59%). The main type of service was the Programa Medicamento em Casa (Home Medication Delivery Program), which was availed by 144 (64%) patients. Women had poorer access to antiviral therapy (56%, p<0.05), and patients registered in the HMDP (68%, p<0.05) had better access. The age group of >48 years represented 70% of the group without access to antiviral therapy. Twenty-two pharmaceutical appointments were conducted through phone calls with patients without access to antiviral therapy.
Conclusion:
This study contributes to the rationalization of efforts in a public health crisis through the identification of groups with the highest risk of poor access to antiviral therapy and the demonstration of the benefits of a medication delivery system.
Related Concept Videos
Retrovirus Life Cycles
Viruses with RNA Genomes
Subviral Agents
Myocarditis III: Medical Management

